Biomedical Engineering Reference
In-Depth Information
polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort
study. Lancet 373:309-317
18. Giusti B, Gori AM, Marcucci R, Saracini C, Il S, Paniccia R, Buonamici P, Antoniucci D,
Abbate R, Gensi GF (2009) Relation of cytochrome P450 2C19 loss-of-function polymor-
phism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103:806-811
19. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients
who are poor metabolizers of the drug.
http://www.fda.gov/Drugs/DrugSafety/Postmarket
20. Holmes DR, Dehmer GJ, Kaul S, Leifer D (2010) ACCF/AHA clopidogrel clinical alert:
approaches to the FDA “Boxed Warning”. J Am Coll Cardiol 56:321-341
21. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanquay JF, Kandzari DE, Cannon CP,
Topol EJ (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent
implantation in patients with high residual platelet reactivity: design and rationale of the
GRAVITAS trial. Am Heart J 157:818-824
22. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von
Beckerath N, Kastrati A (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation,
bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent place-
ment. Circulation 121:512-518
23. Bouman HJ, Parlak E, Van Werkum JWV, Breet NJ, Ten Cate H, Hackeng CM, Ten Berg JM,
Taubert D (2009) Which platelet function test is suitable to monitor clopidogrel responsive-
ness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost
8:482-488
24. Wiviott SD, Antman EM (2004) Clopidogrel resistance. A new chapter in a fast-moving story.
Circulation 109:3064-3067
25. Ksycinska H, Rudzki P, Bukowska-Kiliszek M (2006) Determination of clopidogrel metabo-
lite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 41:533-539
26. Shi BS, Yoo SD (2007) Determination of clopidogrel in human plasma by liquid chromatog-
raphy/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed
Chromatogr 21:883-889
27. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A (2008) Quantitative determination
of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal
48:1219-1224
28. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC,
Barragan P, Dignat-George F, Paganelli F (2008) Adjusted clopidogrel loading dosese accord-
ing to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major
adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol
51:1404-1411
29. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR,
Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR,
Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6(3):193-201
30. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cyto-
chrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and
clinical aspects. Pharmacol Ther 116(3):496-526
31. Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine
glucuronidation. Drug Metab Dispos 25:1-4
32. Williams DG, Patel A, Howard RF (2001) Pharmacogenetics of codeine metabolism in an
urban population of children and its implications for analgesic reliability. Br J Anaesth
86(3):413-421
33. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J (2007) LotschJ, Roots I, Brockmoller J.
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to
CYP2D6 duplication. Pharmacogenomics J 7(4):257-265
34. Lotsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmoller J, Geisslinger G (2009) Can
extremely low or high morphine formation from codeine be predicted prior to therapy initia-
tion? Pain 144:119-124
